期刊文献+

N-苯基-1H-吡咯取代的双苯并咪唑类衍生物的合成及其AT_1受体拮抗活性研究

Synthesis and Biological Activity Evaluation of AT_1 Angiotensin Ⅱ Receptor Antagonists of Dibenzimidazoles with N-Phenyl-1 H-Pyrrole
下载PDF
导出
摘要 目的:寻找活性强、作用时间长的新型非肽类AT1受体拮抗剂。方法:以替米沙坦(telmisartan)为原型物,根据分子-受体结合模型的研究结果对其进行结构优化:运用生物电子等排原理,用苯基吡咯代替联苯结构,在此基础上将羧基与四氮唑两种酸性基团的作用进行比较;改变苯并咪唑2-位亲脂性侧链的长度;在苯基吡咯5-位引入吸电子取代基,共设计了3类结构新颖的N-苯基-1H-吡咯取代的双苯并咪唑类衍生物,并完成了12个目标化合物的合成。通过测定目标化合物抑制AⅡ诱导的兔胸主动脉环收缩的能力评价了其对AT1受体的拮抗活性。结果:目标化合物均未见文献报道,其结构经MS、IR1、H NMR和元素分析确证,其中化合物Ⅰd的AT1受体拮抗活性大于先导物替米沙坦。结论:Ⅰd具有进一步的研究价值。 AIM:To search for the novel angiotensin Ⅱ(A Ⅱ)AT_(1) receptor antagonists with high potency and long duration.METHODS:By use of telmisartan, a potent non-peptide AT_(1) receptor antagonist,as a lead compound and the optimized results of ligand-receptor complex modelling,N-phenylpyrrole with an acid group spacer was compared to the biphenyl bearing an acid group spacer which might provide optimal stereo electronic characteristics.Therefore,12 dibenzimidazoles bearing N-phenyl-1H-pyrrole moiety were designed and synthesized by the replacement of the biphenyl tetrazole with N-phenyl-1H-pyrrole-2-tetrazole and replacement of the tetrazole group with a carboxylic acid moiety,meanwhile introducing different substitutes at the positions-2 of the dibenzimidazole ring and the pyrrole ring.On the other hand,their biological activities were evaluated for antagonism of AⅡ-induced contractions in the rabbit thoracic rings.RESULTS:None of the target compounds has been reported and their structures were identified by IR,(()^(1)H NMR),MS spectra and elemental analysis. And the biological activities were evaluated for antagonism of A Ⅱ-induced contractions in the rabbit thoracic aortic rings.The results of preliminary pharmacological tests showed that compound Ⅰd was more potent than telmisartan.CONCLUSION:Ⅰd is worthy to be intensively investigated further.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2005年第4期296-301,共6页 Journal of China Pharmaceutical University
基金 国家自然科学基金资助项目(No.30371688) 教育部重点资助项目(No.03089)~~
关键词 AT1受体拮抗剂 N-苯基-1 H-吡咯 双苯并咪唑类衍生物 合成 降压 AT_(1)receptor antagonists N-Phenyl-1H-pyrrole Dibenzimidazole derivatives Synthesis Antihypertensive
  • 相关文献

参考文献10

  • 1Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin Ⅱ receptor antagonists[J]. Pharmacol Rev, 1993,45(2) :205 - 251.
  • 2Fukamizu A, Muralami K. Activated and inactivated renin-angiotensin system in transgenic animals-from genes to blood pressure[J]. Lab Anim Sc, 1997,47(2): 127 - 131.
  • 3Cody RJ. The clinical potential of renin inhibitors and angiotensin antagonists[J]. Drugs, 1994,47(4) :586 - 591.
  • 4Duncia JV, Carini AT, Johnson AL, et al. The discovery of DUP-753,a potent orally active non-peptide angiotensin receptor antagonist[J].Med Rev, 1992,12(2): 149 - 158.
  • 5Merlos M, Casas A, Castaner J. Telmisartan BIBR-277 [ J ]. Drugs of the Future,1997,22(10):1 112- 1 116.
  • 6Ries UJ, Mehm G, Narr B, et al. 6-Substituded benzimidazoles as new nonpeptide angiotensin Ⅱ receptor antagonists: synthesis, biological activity, and structure-activity relationship[ J]. J Med Chem , 1993,36(25):4040-4051.
  • 7徐进宜,吉念宁,华维一,吴晓明.非肽类血管紧张素ⅡAT_1受体拮抗剂的定量构效关系研究[J].中国药科大学学报,2005,36(2):99-105. 被引量:6
  • 8Phillpe RB, David BR, Joseph TC, et al. N-Phenyl-1H-pyrrolederivatives are angiotensin Ⅱ receptor antagonists[J]. J Med Chem,1993,36( 1 ): 101 - 110.
  • 9Mantlo NB, Chakravarty PK, Ondeyka DL, et al. Potent, orally activebased angiotensin Ⅱ receptor antagonists[J]. J Med Chem, 1991,34(9) :2 919 -2 922.
  • 10Ahmansa C, Gomez LA, Cavalcanti FL, et al. A diphenylpropionic acids as new AT1 angiotensin Ⅱ receptor antagonists [ J ]. J Med Chem, 1996,39(11) :2 197 - 2 206.

二级参考文献12

  • 1Chang LL, Ashton WT, Flanagen KL, et al.Potent and orally active angiotensin Ⅱ antagonists with equal affinity for the human AT1 and AT2 subtypes[J].J Med Chem ,1995,38:3 741-3 758.
  • 2Anthorry M, Caroline MS,Blair J, et al.Irbesartan, an updated review of its use in cardiovascular disorders[J].Drugs,2000,60(10):1 187-1 206.
  • 3Grey LP, Rachel HF.Eprosartan, a review of its use in the management of hypertension[J].Drugs,2000,60(1):117-201.
  • 4Andrew R, Honghton G.Angiotensin Ⅱ receptor antagonists in chronic heart failure[J].Drugs,2002,62(10):1 433-1 440.
  • 5Toomas P,Jaakko T.The role of angiotensin coverting enzyme inhibitors and angiotensin Ⅱ receptor antagonists in the management of diabetic complications[J].Drugs,2002,62(14):2 007-2 012.
  • 6Mealy N, Ngo J, Castaner T.Antihypertensive angiotensin Ⅱ antagonists ME-3221[J].Drugs of the Future,1996,21(8):794 -798.
  • 7Huang HC,Reitz DB,Chamberlain TS,et al.Synthesis and structure-activity relationships of nonpeptide,potent trizolinone based angiotensin Ⅱreceptor antagonists[J].J Med Chem,1993,36: 2 172-2 181.
  • 8Kiyama R, Honma T,Hqyqshi K,et al.Novel angiotensin Ⅱ receptor antagonists[J].J Med Chem,1995,38:2 728 -2 741.
  • 9Ruth RW,Willian JG,John DL,et al.Nonpeptide angiotensin Ⅱ receptor antagonists: The next generation in antihypertensive therepy[J].J Med Chem,1996,39:625-640.
  • 10廖斌,廖清江.1997年国外研究开发新药概况[J].药学进展,1998,22(2):119-124. 被引量:5

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部